Retrospective study investigating naloxone prescribing and cost in US Medicaid and Medicare patients.

Christopher D Manko Mohamed S Ahmed Lavinia R Harrison Srivastava A KodavatigantiNoelia LugoJason Osei KonaduFarrin KhanCarrie A MassariTenisha K SealeyMaame Efua AddisonCeline N MbahKenneth L McCall Joseph B Fraiman Brian J Piper

Published in: BMJ open (2024)

This pronounced increase in the number of naloxone prescriptions to Medicaid patients from 2018 to 2021 indicates a national response to this widespread public health emergency. Further research into the origins of the pronounced state-level disparities is warranted.

Keyphrases

public health
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
emergency department
prognostic factors
primary care
patient reported outcomes
adverse drug